Headlines 25 years ago this week....

26 March 2006

400 drugs still to prove efficacy in the USA, said the Department of Health and Human Services, following pressure from consumer activist organizations, particularly Ralph Nader's Health Research Group. The efficacy of all prescription drugs approved between 1938 and 1962 was not required to be demonstrated.

UK's House of Lords hits out at parallel importing of drugs, publishing a report that attacks the European Commission's proposal to allow such practices, which claims that PI would put established drugmakers in "an impossible position."

Pharmaceutical trade names should be dropped, says Swedish medical journal, claiming that there are too many and thus confuse, but pharmacists argue that they guarantee the patient always gets the same drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight